Log in to search using one of your social media accounts:


Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

CONCLUSIONSGuadecitabine has promising clinical activity and an acceptable safety profile and thus warrants further development in this population. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research

Related Links:

More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Hematology | Leukemia | Study | Transplants | USA Health